31![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROSCAR safely and effectively. See full prescribing information for PROSCAR. PROSCAR® (finasteride) Tablets Initia HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROSCAR safely and effectively. See full prescribing information for PROSCAR. PROSCAR® (finasteride) Tablets Initia](https://www.pdfsearch.io/img/f0c95beff50fdc3fce9622d090dfd812.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2011-06-10 14:49:28
|
---|
32![For more information about the Organization of Teratology Information Specialists or to find a service in your area, call[removed]or visit us online at: www.OTISpregnancy.org. Finasteride (Propecia®/Proscar®) an For more information about the Organization of Teratology Information Specialists or to find a service in your area, call[removed]or visit us online at: www.OTISpregnancy.org. Finasteride (Propecia®/Proscar®) an](https://www.pdfsearch.io/img/e69fa0ee2e5ef6e0f51862411525b740.jpg) | Add to Reading ListSource URL: www.mothertobaby.orgLanguage: English - Date: 2011-10-04 12:49:35
|
---|
33![Article pubs.acs.org/jmc Development of Potent and Selective Inhibitors of Aldo−Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure−Activity Article pubs.acs.org/jmc Development of Potent and Selective Inhibitors of Aldo−Keto Reductase 1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase) Based on N-Phenyl-Aminobenzoates and Their Structure−Activity](https://www.pdfsearch.io/img/90ff3bbf6bfd6fa78422325a603beffb.jpg) | Add to Reading ListSource URL: www.itmat.upenn.eduLanguage: English - Date: 2012-03-19 10:59:01
|
---|
34![------------------------------ CONTRAINDICATIONS ------------------------------Hypersensitivity to any components of this product (4). Women who are or may potentially be pregnant (4, 5.4, 8.1, 16). ------------------------------ CONTRAINDICATIONS ------------------------------Hypersensitivity to any components of this product (4). Women who are or may potentially be pregnant (4, 5.4, 8.1, 16).](https://www.pdfsearch.io/img/0bc14364dfdc9bf954c3545c233eab01.jpg) | Add to Reading ListSource URL: www.merck.comLanguage: English - Date: 2013-09-13 16:58:27
|
---|
35![Questions to Ask Your Doctor about BPH Treatment What are the best ways to treat BPH? Am I a candidate for “watchful waiting”?
Questions to Ask Your Doctor about BPH Treatment What are the best ways to treat BPH? Am I a candidate for “watchful waiting”?](https://www.pdfsearch.io/img/19e0f73197cf04545ca6528873c91374.jpg) | Add to Reading ListSource URL: www.prostate.netLanguage: English - Date: 2013-09-11 06:51:23
|
---|
36![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROPECIA safely and effectively. See full prescribing information HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROPECIA safely and effectively. See full prescribing information](https://www.pdfsearch.io/img/593e00a7defb398765de3355efa4872f.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2014-02-03 14:52:53
|
---|
37![Proscar (finasteride) tablets label Proscar (finasteride) tablets label](https://www.pdfsearch.io/img/cc6feec451b8412109634f132ef054c9.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2010-10-05 09:53:16
|
---|
38![THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 8, Number 2, 2002, pp. 143–152 © Mary Ann Liebert, Inc. THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 8, Number 2, 2002, pp. 143–152 © Mary Ann Liebert, Inc.](https://www.pdfsearch.io/img/813b6b1478241a352c764cac7dd9e59e.jpg) | Add to Reading ListSource URL: www.haargroeispecialist.nlLanguage: English - Date: 2012-08-03 04:40:49
|
---|
39![• Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5α-reductase inhibitors. (4) • Patients with previously demonstrated, clinically significant hypersensitivity (e.g., serious skin reactions, angioedema) to AVODART or other 5α-reductase inhibitors. (4)](https://www.pdfsearch.io/img/da0b37383b9b4d85f7763990d8ca62cf.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2010-09-09 19:11:22
|
---|
40![------------------------------ CONTRAINDICATIONS ------------------------------ Hypersensitivity to any components of this product (4). ------------------------------ CONTRAINDICATIONS ------------------------------ Hypersensitivity to any components of this product (4).](https://www.pdfsearch.io/img/7e65ddefa5e4d20faf333746391dcb57.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2012-04-11 12:54:06
|
---|